Atorvastatin normalizes endothelial function in healthy smokers

Stefan Agewall1, Asa Hernberg

  • 1Department of Cardiology, Karolinska University Hospital, Karolinska Institute, S 14186 Stockholm, Sweden. stefan.agewall@karolinska.se

Insights

Atorvastatin treatment significantly improved endothelial function in smokers with normal cholesterol levels. This improvement in flow-mediated dilation (FMD) occurred independently of changes in LDL cholesterol, suggesting statins benefit smokers

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Endothelial Biology

Background:

  • Endothelial dysfunction is a predictor of cardiovascular disease.
  • Smokers often exhibit impaired endothelial function, even with normal lipid profiles.
  • Statins are primarily known for lipid-lowering effects but may have pleiotropic vascular benefits.

Purpose of the Study:

  • To investigate the effect of atorvastatin on endothelial function in smokers with normal cholesterol.
  • To compare atorvastatin's impact on endothelial function between smokers and non-smokers.
  • To determine if improvements in endothelial function are linked to LDL cholesterol reduction.

Main Methods:

  • Open-label, randomized cross-over study involving 20 healthy smokers and 20 non-smokers.
  • Participants received either 80 mg of atorvastatin or placebo.
  • Endothelial function was assessed using flow-mediated dilation (FMD) measurements.

Main Results:

  • Smokers had significantly lower baseline FMD compared to non-smokers (2.2% vs. 4.5%, P<0.05).
  • Atorvastatin treatment increased FMD in smokers (to 4.0%, P<0.05), with levels returning to baseline during placebo.
  • Atorvastatin had no significant effect on FMD in non-smokers, and changes in FMD were not correlated with LDL cholesterol reduction.

Conclusions:

  • High-dose atorvastatin (80 mg) can improve endothelial function in smokers with normal lipid levels.
  • The beneficial effect of atorvastatin on endothelial function in smokers is independent of its LDL-lowering capacity.
  • Statin therapy may represent a therapeutic strategy to mitigate endothelial dysfunction associated with smoking.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...